NorthStrive Patents Muscle-Preservation Tech to Pair With GLP-1 Weight Loss Drugs
NorthStrive Biosciences files patents targeting muscle loss — a major side effect of GLP-1 obesity drugs — using peptide and microbiome tech.
Summary
As GLP-1 drugs like semaglutide reshape obesity treatment, a critical drawback has emerged: significant muscle loss alongside fat loss. NorthStrive Biosciences, a subsidiary of PMGC Holdings, has filed two US patent applications for technologies aimed at preserving lean muscle mass in people using GLP-1 and next-generation obesity therapies. Their EL-22 program uses peptide technology, while EL-32 involves engineered beneficial bacteria. Both are designed to work alongside weight-loss drugs, not replace them. The filings cover a wide range of delivery methods and include compounds like apelin and ursolic acid, known for muscle support. While these are early-stage patent filings — not proven therapies — they signal a growing commercial and scientific focus on protecting muscle during weight loss, a concern deeply relevant to metabolic health and healthy aging.
Detailed Summary
Muscle loss during weight loss has emerged as one of the most pressing unresolved problems in modern obesity medicine. GLP-1 receptor agonists have transformed how millions of people manage their weight, but research increasingly shows that a meaningful portion of weight lost on these drugs comes from lean muscle tissue — not just fat. That matters enormously for long-term health, metabolic function, and physical independence as people age.
NorthStrive Biosciences has filed two US patent applications — EL-22 (patent app 19/709,895) and EL-32 (19/709,950) — specifically targeting muscle preservation in people undergoing weight-loss treatment. EL-22 is a peptide-based technology, while EL-32 relies on bioengineered microorganisms, including strains of beneficial gut bacteria. Both aim to counteract muscle wasting that can occur during caloric restriction or GLP-1 drug use.
The patent claims are notably broad, covering oral, injectable, nasal, and topical delivery formats, as well as combination strategies involving apelin and ursolic acid — compounds with established associations with muscle support. The filings also extend to muscle decline linked to aging, malnutrition, inactivity, and neurological conditions, suggesting NorthStrive sees a wider therapeutic landscape beyond obesity alone.
Strategically, the company appears to be positioning these technologies as companion treatments to GLP-1 drugs — a potentially large and underserved adjacent market as obesity pharmacotherapy matures. Covering both peptide and microbiome-based platforms simultaneously could be an attempt to control multiple pathways to the same therapeutic goal.
Important caveats apply. Patent filings are not clinical proof. There is no published efficacy or safety data for EL-22 or EL-32 in humans. This is early-stage intellectual property strategy, not a regulatory milestone. Health-conscious readers should track this space but wait for peer-reviewed trial data before drawing conclusions about clinical utility.
Key Findings
- NorthStrive filed two patents targeting muscle preservation specifically for people using GLP-1 obesity drugs.
- EL-22 uses peptide technology; EL-32 uses engineered beneficial bacteria — two distinct biological approaches to the same goal.
- Patent claims cover oral, injectable, nasal, and topical delivery, plus combinations with apelin and ursolic acid.
- Applications extend beyond obesity to aging-related muscle decline, malnutrition, and neurological conditions.
- No human efficacy data exists yet — these are early-stage IP filings, not approved or proven therapies.
Methodology
This is a news report from Longevity.Technology summarizing a corporate press release about patent filings by PMGC Holdings subsidiary NorthStrive Biosciences. No peer-reviewed clinical data is cited. Evidence basis is limited to patent application numbers and company statements.
Study Limitations
No clinical trial data or peer-reviewed research on EL-22 or EL-32 in humans is available. Patent filings indicate commercial intent, not therapeutic efficacy or safety. Independent verification of scientific claims requires access to the actual patent documents and future published studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: